Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 1;37(2):79-85.
doi: 10.1097/MOG.0000000000000704.

Mechanisms of autoimmune hepatitis

Affiliations
Review

Mechanisms of autoimmune hepatitis

Anaïs Cardon et al. Curr Opin Gastroenterol. .

Abstract

Purpose of review: Autoimmune hepatitis (AIH) is a chronic disease characterized by a lymphocyte infiltrate in the liver. For decades, nonspecific immunosuppression has been used to limit chronic liver inflammation. The high risk of relapse, the treatments side effects, and the significant number of refractory patients are the main clinical issues that require efforts to understand AIH immune mechanisms.

Recent findings: The balance between regulatory CD4 T cells, known to control autoimmunity, and effector CD4 T cells, that recognize liver self-antigens and mediate the liver inflammation, appears central in AIH immune mechanisms. Recent advances in the identification of pathogenic auto-reactive CD4 T cells, and of new mechanisms of immune regulatory defects in AIH patients, give new insights into the pathophysiology of this disease.

Summary: In this review, we propose an overview of the central role of CD4 T cells (both regulatory and pathogenic) in mechanisms of AIH, with a focus on recent advances regarding defective regulatory mechanisms and immune profile of auto-reactive CD4 T cells. These findings may have implication for the orientation of new therapeutic strategies to treat AIH, such as regulatory T-cell infusion or targeting B cells and cytokines released by pathogenic CD4 T cells.

PubMed Disclaimer

References

    1. Rigopoulou EI, Zachou K, Gatselis N, et al. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol 2013; 13:127–135.
    1. Herkel J, Carambia A, Lohse AW. Autoimmune hepatitis: possible triggers, potential treatments. J Hepatol 2020; 73:446–448.
    1. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193–2213.
    1. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010; 34:7–14.
    1. van Gerven NMF, de Boer YS, Zwiers A, et al. HLA-DRB1∗03:01 and HLA-DRB1∗04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 2015; 16:247–252.

Publication types

LinkOut - more resources